Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Reports Strong Q1 2026 Financial Results and Key Program Updates
Summary
Ionis Pharmaceuticals, Inc. reported a strong first quarter of 2026 with an 87% increase in revenue compared to the same period in 2025, driven by commercial success and robust R&D revenue. The company improved its 2026 financial guidance, reflecting strong year-to-date performance and positive outlook. Key highlights include the acceptance of sNDA for olezarsen by the FDA for Priority Review, the acceptance of NDA for zilganersen by the FDA for Priority Review, and the achievement of the primary endpoint in the B-Well Phase 3 studies for bepirovirsen. Ionis also provided updates on its product launches and regulatory milestones, including the launch of TRYNGOLZA in the EU and the expanded access program for zilganersen in the U.S.
Profitelligence Alerts
Get alerts for IONS
Be first to know when Ionis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Official SEC Documents
Advertisement